ConductScience.org, home

Paper20175274

Toxic vitreitis outbreak after intravitreal injection.

Ness T and 4 others. Retina, 2010. Cited by 41 papers, by iCite.

Cite this record

ConductScience Library. Toxic vitreitis outbreak after intravitreal injection. Papers, record 20175274. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20175274

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Toxic vitreitis outbreak after intravitreal injection.
PubMed
Journal
Retina
PubMed
Year
2010
PubMed
Publication types
Case Reports, Journal Article
PubMed
Citations, by iCite
41
iCite
Relative citation ratio, by iCite
1.57
iCite
Revised in PubMed
2022-04-08
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ness TThomas
2Feltgen NNiklas
3Agostini HHansjuergen
4Böhringer DDaniel
5Lubrich BBeate

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Disease OutbreaksMajor topic
Eye DiseasesMajor topic
SyringesMajor topic
Vitreous BodyMajor topic
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Bevacizumab
Female
Humans
Injections
Macular Degeneration
Macular Edema
Male
Ranibizumab
Retinal Hemorrhage
Retrospective Studies
Suppuration
Triamcinolone Acetonide

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in21336079Toxic vitreitis outbreak after intravitreal injection.https://conductscience.org/library/papers/21336079

Source PubMed

Download CSV of comments and corrections

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.

PMIDTitleJournalYearIn PapersSource
38223782Retinal Vasculitis After Intravitreal Pegcetacoplan: Report From the ASRS Research and Safety in Therapeutics (ReST) Committee.J Vitreoretin Dis2024https://conductscience.org/library/papers/38223782PubMed
37197577Impact of Modifying Abicipar Manufacturing Process in Patients with Neovascular Age-Related Macular Degeneration: MAPLE Study Results.Clin Ophthalmol2023https://conductscience.org/library/papers/37197577PubMed
35715871Ocular inflammation after agitation of siliconized and silicone oil-free syringes: a randomized, double-blind, controlled clinical trial.Int J Retina Vitreous2022https://conductscience.org/library/papers/35715871PubMed
35194509Toxic Intraocular Syndrome.J Ophthalmic Vis Res2022https://conductscience.org/library/papers/35194509PubMed
34932153Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD.Graefes Arch Clin Exp Ophthalmol2022https://conductscience.org/library/papers/34932153PubMed
34604691Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis.J Vitreoretin Dis2021https://conductscience.org/library/papers/34604691PubMed
33631912Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection.Turk J Ophthalmol2021https://conductscience.org/library/papers/33631912PubMed
32789284Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab.J Vitreoretin Dis2020https://conductscience.org/library/papers/32789284PubMed
31156880Assessment of bevacizumab quality and stability in repackaged syringes for clinical use.Eur J Hosp Pharm2016https://conductscience.org/library/papers/31156880PubMed
29802422[Endophthalmitis].Ophthalmologe2018https://conductscience.org/library/papers/29802422PubMed
23788205Quality of bevacizumab compounded for intravitreal administration.Eye (Lond)2013https://conductscience.org/library/papers/23788205PubMed
23559321[Reliability and safety of intravitreal Ozurdex injections. The ZERO study].Ophthalmologe2014https://conductscience.org/library/papers/23559321PubMed
23307955Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF/VEGFR2 pathway.Invest Ophthalmol Vis Sci2013https://conductscience.org/library/papers/23307955PubMed
22983424Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications.Angiogenesis2013https://conductscience.org/library/papers/22983424PubMed
22048244Endophthalmitis following intravitreal injections.Graefes Arch Clin Exp Ophthalmol2012https://conductscience.org/library/papers/22048244PubMed
21705685Hyperoxia therapy of pre-proliferative ischemic retinopathy in a mouse model.Invest Ophthalmol Vis Sci2011https://conductscience.org/library/papers/21705685PubMed
21051703Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling.Invest Ophthalmol Vis Sci2011https://conductscience.org/library/papers/21051703PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20175274

GET https://conductscience.org/api/papers/v1/20175274/authors